PRLD

Prelude Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↓ 4/10
  • Momentum↑ 9/10
Prelude Therapeutics sales and earnings growth
PRLD Growth
Neutral
  • Revenue Y/Y↑ 116.67%
  • EPS Y/Y↑ 17.42%
  • FCF Y/Y↑ 6.77%
Prelude Therapeutics gross and profit margin trends
PRLD Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1719.60%
  • ROIC↓ -120.10%
Prelude Therapeutics net debt vs free cash flow
PRLD Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Prelude Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗